Premium
Effects of enteric‐coated, low‐dose aspirin on parameters of platelet function
Author(s) -
Van Hecken A.,
Juliano M. L.,
Depré M.,
De Lepeleire I.,
Arnout J.,
Dynder A.,
Wildonger L.,
Petty K. J.,
Gottesdiener K.,
De Hoon J. N.
Publication year - 2002
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2002.01332.x
Subject(s) - enteric coating , aspirin , medicine , placebo , platelet , thromboxane , thromboxane b2 , arachidonic acid , enteric coated , gastroenterology , pharmacology , ex vivo , dosage form , chemistry , in vitro , biochemistry , pathology , alternative medicine , enzyme
SUMMARY Background : Aspirin is widely used as an anti‐thrombotic drug; however, it has been suggested that enteric‐coated formulations of aspirin may be less bioavailable and less effective as anti‐thrombotic agents. Aim : To assess the effect of a formulation of enteric‐coated, low‐dose (81 mg) aspirin on serum generated thromboxane B 2 and platelet aggregation in healthy subjects. Methods : Twenty‐four subjects participated in a double‐blind, randomized, placebo‐controlled, parallel‐group, multiple‐dose study. Twelve subjects in each of two groups received a daily oral dose of enteric‐coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B 2 and platelet aggregation (using 1 m m arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7. Results : After seven daily doses of enteric‐coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B 2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid‐ and collagen‐induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric‐coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo. Conclusions : The anti‐platelet effects of multiple, daily, low‐dose aspirin (as assessed by inhibition of serum thromboxane B 2 and platelet aggregation) are not adversely affected by enteric coating.